Study of Safety and Pharmacokinetics of Oral Doses of EPX-100 in Healthy Subjects.
Condition(s):Dravet SyndromeLast Updated:June 25, 2020Completed
Hide Studies Not Open or Pending
Condition(s):Dravet SyndromeLast Updated:June 25, 2020Completed
Condition(s):Dravet Syndrome; Dravet Syndrome, IntractableLast Updated:November 9, 2022Not yet recruiting
Condition(s):Dravet Syndrome; Depression; AnxietyLast Updated:December 14, 2023Withdrawn
Condition(s):Epilepsies, MyoclonicLast Updated:January 19, 2024Recruiting
Condition(s):Epilepsies, Myoclonic; Drug Resistant EpilepsyLast Updated:June 9, 2023Available
Condition(s):Dravet Syndrome; Lennox Gastaut SyndromeLast Updated:December 16, 2021Withdrawn
Condition(s):EpilepsyLast Updated:February 16, 2023Completed
Condition(s):Lennox-Gastaut Syndrome; Dravet SyndromeLast Updated:August 30, 2022Terminated
Condition(s):Dravet Syndrome (DS); Lennox-Gastaut Syndrome (LGS)Last Updated:January 25, 2024Recruiting
Condition(s):Dravet Syndrome; Lennox Gastaut Syndrome; Developmental and Epileptic EncephalopathiesLast Updated:February 28, 2024Available
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.